Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short- and long-term outcomes in children born after assisted reproductive technology

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Re: Vitamin D and gestational diabetes mellitus: a systematic review based on data free of Hawthorne effect

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Left Atrial Function in Heart Failure With Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate the effect on fetal growth of treatment with oral beta-blockers during pregnancy in women with congenital or acquired heart disease.

DESIGN: Historical matched cohort study.

SETTING: Centre for Pregnant Women with Heart Disease, Copenhagen University Hospital, Denmark.

POPULATION: A cohort of 175 women with heart disease, grouped according to beta-blocker treatment, and a cohort of 627 women from the overall population matched on seven birthweight-determining factors.

METHODS: Differences between groups were tested by simple descriptive statistics and assessed using standard hypothesis tests. Associations were estimated by correlational analysis and multivariable regression.

MAIN OUTCOME MEASURE: Proportion of infants born small for gestational age (SGA).

RESULTS: More of the infants exposed to beta-blockers were SGA compared with non-exposed infants (29.4 versus 15.3%; P < 0.05). After adjustment for birthweight-determining factors, beta-blocker treatment and maternal body mass index (BMI) were the only factors independently associated with SGA (the relative difference in expected birthweight was -8.6%; 95% CI -13.3 to -3.9%; P = 0.0004). After adjustment for BMI, beta-blocker treatment was associated with an increased risk of SGA (OR 2.65; 95% CI 1.15-6.10; P = 0.02). In a subgroup with isolated tachyarrhythmias, SGA infants were more frequent in the beta-blocker exposed group compared with the non-exposed group (31 versus 10%; P < 0.005). Beta-blocker treatment was the only independent predictor of SGA, adjusting for several factors influencing fetal growth (the relative difference in expected birthweight was -12.2%; 95% CI -19.9 to -3.9%; P = 0.001).

CONCLUSIONS: In a historical cohort of pregnancies complicated by maternal heart disease, treatment with beta-blockers was found to be independently associated with an increased risk of delivering an SGA infant.

Original languageEnglish
JournalBJOG : an international journal of obstetrics and gynaecology
Volume121
Issue number5
Pages (from-to)618-26
Number of pages9
ISSN1470-0328
DOIs
Publication statusPublished - Apr 2014

    Research areas

  • Administration, Oral, Adrenergic beta-Antagonists, Adult, Body Mass Index, Case-Control Studies, Cohort Studies, Female, Fetal Growth Retardation, Heart Diseases, Humans, Infant, Newborn, Infant, Small for Gestational Age, Pregnancy, Pregnancy Complications, Cardiovascular

ID: 45030534